Product Description
AZD0328 is a potent, stereo-selective, full agonist of the human alpha7 nAChR. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd0328.html)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cognitive Dysfunction|Parkinson's Disease|Schizophrenia
Phase 1: Healthy Volunteers|Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00752830 |
D0190C00009 | P1 |
Completed |
Healthy Volunteers |
2008-10-01 |
2019-03-18 |
||
NCT00738959 |
D0190C00008 | P1 |
Completed |
Healthy Volunteers |
2008-10-01 |
2019-03-18 |
Treatments |
|
NCT00687141 |
D0190C00006 | P1 |
Completed |
Alzheimer Disease |
2008-06-01 |
2019-03-18 |
Treatments |
|
NCT04810104 |
PD-MIND | P2 |
Withdrawn |
Parkinson's Disease|Cognitive Dysfunction |
2024-01-01 |
69% |
2022-10-15 |
Primary Endpoints |
NCT00669903 |
D0190C00007 | P2 |
Terminated |
Schizophrenia |
2008-11-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|